AbFlowNet: Optimizing Antibody-Antigen Binding Energy via Diffusion-GFlowNet Fusion
By: Abrar Rahman Abir , Haz Sameen Shahgir , Md Rownok Zahan Ratul and more
Potential Business Impact:
Designs better antibodies that stick to targets.
Complementarity Determining Regions (CDRs) are critical segments of an antibody that facilitate binding to specific antigens. Current computational methods for CDR design utilize reconstruction losses and do not jointly optimize binding energy, a crucial metric for antibody efficacy. Rather, binding energy optimization is done through computationally expensive Online Reinforcement Learning (RL) pipelines rely heavily on unreliable binding energy estimators. In this paper, we propose AbFlowNet, a novel generative framework that integrates GFlowNet with Diffusion models. By framing each diffusion step as a state in the GFlowNet framework, AbFlowNet jointly optimizes standard diffusion losses and binding energy by directly incorporating energy signals into the training process, thereby unifying diffusion and reward optimization in a single procedure. Experimental results show that AbFlowNet outperforms the base diffusion model by 3.06% in amino acid recovery, 20.40% in geometric reconstruction (RMSD), and 3.60% in binding energy improvement ratio. ABFlowNet also decreases Top-1 total energy and binding energy errors by 24.8% and 38.1% without pseudo-labeling the test dataset or using computationally expensive online RL regimes.
Similar Papers
FP-AbDiff: Improving Score-based Antibody Design by Capturing Nonequilibrium Dynamics through the Underlying Fokker-Planck Equation
Machine Learning (CS)
Creates better medicines by designing perfect antibody shapes.
dyAb: Flow Matching for Flexible Antibody Design with AlphaFold-driven Pre-binding Antigen
Quantitative Methods
Designs better medicines by predicting how they change.
Learning from B Cell Evolution: Adaptive Multi-Expert Diffusion for Antibody Design via Online Optimization
Machine Learning (CS)
Designs better antibodies for specific sicknesses.